Metabolomics Workbench : NIH Data Repository

Analysis	Metabolite Name	Measured Value	Units	CASE_CONTROL	Chemotherapy	Drug	Race	TIMEPOINT	Tamoxyfen	Taxane
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	117247	Peak area	Control	Y	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	118933	Peak area	Case	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	126343	Peak area	Control	N	Letrozole	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	135899	Peak area	Case	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	136477	Peak area	Case	N	Letrozole	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	144150	Peak area	Case	N	Letrozole	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	166253	Peak area	Case	Y	Letrozole	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	167667	Peak area	Case	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	199559	Peak area	Case	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	206406	Peak area	Case	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	245263	Peak area	Control	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	247122	Peak area	Control	Y	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	247645	Peak area	Case	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	249171	Peak area	Control	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	260241	Peak area	Case	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	260831	Peak area	Control	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	264298	Peak area	Control	Y	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	266484	Peak area	Control	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	268865	Peak area	Case	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	275648	Peak area	Control	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	277902	Peak area	Control	N	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	288730	Peak area	Control	Y	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	289376	Peak area	Control	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	299489	Peak area	Case	Y	Letrozole	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	302223	Peak area	Control	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	304080	Peak area	Control	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	312057	Peak area	Case	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	315243	Peak area	Case	Y	Exemestane	Black	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	315295	Peak area	Control	N	Letrozole	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	330111	Peak area	Case	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	343059	Peak area	Control	Y	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	354809	Peak area	Case	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	364303	Peak area	Control	Y	Letrozole	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	367538	Peak area	Case	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	376318	Peak area	Control	N	Exemestane	Black	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	376637	Peak area	Case	N	Letrozole	Black	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	391107	Peak area	Case	N	Exemestane	Black	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	400962	Peak area	Control	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	404325	Peak area	Control	N	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	404868	Peak area	Case	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	418876	Peak area	Case	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	419005	Peak area	Control	N	Letrozole	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	424605	Peak area	Control	Y	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	428449	Peak area	Control	Y	Exemestane	White	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	429727	Peak area	Control	Y	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	432892	Peak area	Control	N	Letrozole	Black	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	433850	Peak area	Control	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	438116	Peak area	Control	Y	Letrozole	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	442199	Peak area	Control	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	444554	Peak area	Case	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	448497	Peak area	Case	N	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	454072	Peak area	Case	Y	Exemestane	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	460388	Peak area	Control	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	469129	Peak area	Case	N	Exemestane	Black	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	471336	Peak area	Case	N	Letrozole	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	478436	Peak area	Control	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	481771	Peak area	Case	N	Letrozole	Black	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	493875	Peak area	Control	N	Letrozole	Black	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	495052	Peak area	Control	Y	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	502740	Peak area	Case	N	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	503593	Peak area	Control	N	Exemestane	Black	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	503992	Peak area	Case	N	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	511065	Peak area	Control	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	533478	Peak area	Control	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	536888	Peak area	Control	Y	Letrozole	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	537173	Peak area	Case	Y	Exemestane	Black	3 Month	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	539096	Peak area	Case	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	543180	Peak area	Case	N	Letrozole	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	564288	Peak area	Control	Y	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	568299	Peak area	Control	Y	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	572237	Peak area	Case	N	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	584761	Peak area	Case	Y	Exemestane	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	586951	Peak area	Control	Y	Letrozole	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	598348	Peak area	Case	Y	Exemestane	White	Baseline	N	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	623808	Peak area	Control	N	Letrozole	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	631397	Peak area	Control	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	648299	Peak area	Case	Y	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	649100	Peak area	Case	Y	Exemestane	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	651784	Peak area	Control	N	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	653056	Peak area	Case	N	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	669760	Peak area	Case	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	679424	Peak area	Case	Y	Letrozole	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	712709	Peak area	Case	Y	Exemestane	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	722320	Peak area	Case	Y	Letrozole	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	731096	Peak area	Case	N	Letrozole	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	738327	Peak area	Control	Y	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	759108	Peak area	Control	Y	Exemestane	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	787260	Peak area	Control	N	Letrozole	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	787686	Peak area	Case	Y	Letrozole	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	870079	Peak area	Control	Y	Exemestane	White	Baseline	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	876175	Peak area	Case	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	876883	Peak area	Case	Y	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	966642	Peak area	Control	N	Exemestane	White	3 Month	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	977111	Peak area	Case	Y	Letrozole	White	3 Month	Y	Y
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1034169	Peak area	Control	N	Letrozole	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1084616	Peak area	Control	N	Letrozole	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1359467	Peak area	Case	N	Exemestane	White	Baseline	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1451165	Peak area	Case	Y	Exemestane	White	3 Month	Y	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1461330	Peak area	Control	Y	Exemestane	White	Baseline	N	N
Reversed phase NEGATIVE ION MODE	DOCOSAHEXAENOIC ACID (CAS# 6217-54-5 ); (M-H)-	1467569	Peak area	Case	Y	Exemestane	White	Baseline	Y	N